77 related articles for article (PubMed ID: 6358423)
1. Effects of recombinant interferon-alpha on immune function in cancer patients.
Maluish AE; Leavitt R; Sherwin SA; Oldham RK; Herberman RB
J Biol Response Mod; 1983; 2(5):470-81. PubMed ID: 6358423
[TBL] [Abstract][Full Text] [Related]
2. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
[TBL] [Abstract][Full Text] [Related]
3. Changes in immune function in patients receiving natural leukocyte interferon.
Maluish AE; Ortaldo JR; Sherwin SA; Oldham RK; Herberman RB
J Biol Response Mod; 1983; 2(5):418-27. PubMed ID: 6644346
[TBL] [Abstract][Full Text] [Related]
4. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
[TBL] [Abstract][Full Text] [Related]
5. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
[TBL] [Abstract][Full Text] [Related]
6. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
7. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
10. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
11. Preliminary observations of immunomodulatory activity of lymphoblastoid interferon-alpha administered every other day or weekly.
Neefe JR; Sullivan JE; Silgals R
J Biol Response Mod; 1983; 2(5):441-9. PubMed ID: 6644348
[TBL] [Abstract][Full Text] [Related]
12. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
Edwards BS; Hawkins MJ; Borden EC
J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effect of human fibroblast interferon on malignant cancer. (2) Immunological study of the patients under treatment].
Ezaki K; Okabe K; Domyo M; Abe K; Ogawa M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):238-43. PubMed ID: 7184400
[TBL] [Abstract][Full Text] [Related]
14. Augmented immunity in cancer patients treated with alpha-interferon.
Neefe JR; Sullivan JE; Ayoob M; Phillips E; Smith FP
Cancer Res; 1985 Feb; 45(2):874-8. PubMed ID: 3967248
[TBL] [Abstract][Full Text] [Related]
15. Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients.
Silver HK; Connors JM; Karim KA; Kong S; Spinelli JJ; de Jong G; McLean DM; Salinas FA
J Biol Response Mod; 1983; 2(5):428-40. PubMed ID: 6644347
[TBL] [Abstract][Full Text] [Related]
16. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
17. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
Koren HS; Brandt CP; Tso CY; Laszlo J
J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
[TBL] [Abstract][Full Text] [Related]
18. Effect of in vivo administration of interferon on human monocyte function.
Territo M; Sarna G; Figlin R
J Biol Response Mod; 1983; 2(5):450-7. PubMed ID: 6644349
[TBL] [Abstract][Full Text] [Related]
19. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
20. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
Colotta F; Peri G; Villa A; Mantovani A
J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]